Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

NCT02758587 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-small-cell Lung
Mesothelioma
Pancreatic Neoplasms

Interventions

DRUG: Defactinib
DRUG: Pembrolizumab

Sponsor

NHS Greater Glasgow and Clyde

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]